faricimab + aflibercept

This entry refers to the **combination of two separate pharmaceuticals administered as individual drugs, not as a fixed-dose commercial co-formulation**. - **Faricimab** is a bispecific monoclonal antibody designed for intravitreal injection to treat retinal vascular diseases. It targets and inhibits both **vascular endothelial growth factor-A (VEGF-A)** and **angiopoietin-2 (Ang-2)**, two pathways central to the pathogenesis of diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Its dual inhibition offers extended durability compared to other anti-VEGF agents[2][3][5]. - **Aflibercept** is a recombinant fusion protein acting as a soluble decoy receptor that binds VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing these ligands from activating their native receptors. It is also used to treat nAMD, DME, and other retinal vascular diseases, with a distinct molecular structure and broad spectrum VEGF/PlGF inhibition[5]. - Both drugs are injected via the intravitreal route and, though often compared or used sequentially, are **not officially combined in a single marketed product or therapy**. - Clinical research and real-world studies have explored switching between these agents, particularly moving patients from aflibercept to faricimab in cases of insufficient response, often observing improved anatomical or functional outcomes in some patients[1][4][6][7].